CRNX’s 52-Week Rollercoaster: From $15.76 to $53.70 – What’s Next for Investors?

TOST Stock

Crinetics Pharmaceuticals Inc experienced a rather steady stock market performance. The highest value in the past year was recorded at $53.70 on 05/22/24 and the lowest value was $15.76 on 09/08/23.

52-week price history of CRNX Stock

Studying a stock’s 52-week price history, which includes both low and high prices, can help gauge its current status and potential future performance. Crinetics Pharmaceuticals Inc’s current trading price is -10.19% away from its 52-week high, while its distance from the 52-week low is 206.03%. The stock’s price range during the 52-week period has remained between $15.76 and $53.70. In the Healthcare sector, the company’s shares saw a trading volume of around 0.72 million for the day, which was evidently lower than the average daily volume of 0.9 million over the past three months.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Market Capitalization and Financial Performance: An In-Depth Look

Crinetics Pharmaceuticals Inc (CRNX) has experienced a quarterly rise of 3.85% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 3.80B and boasts a workforce of 290 employees.

Making Sense of Trading Volume and Moving Average Data

Based on Barchart.com data, the company’s moving average over the 100-day period was 44.60, with a change in price of +12.24. Similarly, Crinetics Pharmaceuticals Inc recorded 900,183 in trading volume during the last 100 days, posting a change of +34.01%.

Examining CRNX’s Debt-to-Equity Ratio: What You Need to Know

The debt-to-equity (D/E) ratio is a crucial measure that sheds light on a company’s financial health and market standing. It is determined by dividing a company’s overall liabilities by its shareholders’ equity, showing the extent of a company’s debt usage in financing its assets compared to the shareholders’ equity. At the time of writing, the total D/E ratio for CRNX stands at 0.06. Similarly, the long-term debt-to-equity ratio is also 0.05.

CRNX Stock Stochastic Average

Crinetics Pharmaceuticals Inc’s raw stochastic average for the past 50 days is presently 56.90%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 99.31%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 66.12% and 52.03%, respectively.

CRNX Stock Price Performance Analysis

A mixed performance in the stock price over the year has left investors with either an optimistic or pessimistic outlook, depending on their point of view. This year’s metric has recorded a Price increase of 35.55%. However, over the past six months, we’ve seen a weaker performance of 38.75%. The price of CRNX fallen by 5.21% over the last 30 days. And in the last five days, it has surged by 4.69%.

Most Popular